Study of AK112 in the Treatment of Advanced Gynecological Tumors

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.

Phase 2

Akeso